Pharmaceutical company AstraZeneca announced Tuesday that its medication Ultomiris successfully achieved the primary objective in a major clinical study, demonstrating decreased protein levels in urine among patients suffering from IgA nephropathy, an uncommon kidney condition.
According to the company’s preliminary data analysis, the treatment produced statistically meaningful outcomes by the 34th week in adult patients facing potential disease advancement. The pharmaceutical firm noted that protein level reductions became apparent as early as the 10th week of treatment.
IgA nephropathy represents an uncommon inflammatory kidney condition where irregular proteins accumulate within the kidneys, causing inflammation that damages their blood-filtering capabilities. Without proper treatment, this condition can advance to chronic kidney disease and potentially progress to complete kidney failure.
The pharmaceutical company stated its intention to pursue expedited regulatory approval for this new use in major global markets while extending the clinical study to evaluate kidney function changes at the 106-week mark, which serves as the trial’s secondary main objective.
The medication Ultomiris, scientifically referred to as ravulizumab, currently holds regulatory approval across the United States, European Union, and Japan for addressing specific uncommon blood conditions and neurological disorders.
According to company officials, the medication’s safety characteristics remained in line with previously established risk factors, with no additional safety issues emerging during the study.
